Logo video2dn
  • ะกะพั…ั€ะฐะฝะธั‚ัŒ ะฒะธะดะตะพ ั ัŽั‚ัƒะฑะฐ
  • ะšะฐั‚ะตะณะพั€ะธะธ
    • ะœัƒะทั‹ะบะฐ
    • ะšะธะฝะพ ะธ ะะฝะธะผะฐั†ะธั
    • ะะฒั‚ะพะผะพะฑะธะปะธ
    • ะ–ะธะฒะพั‚ะฝั‹ะต
    • ะกะฟะพั€ั‚
    • ะŸัƒั‚ะตัˆะตัั‚ะฒะธั
    • ะ˜ะณั€ั‹
    • ะ›ัŽะดะธ ะธ ะ‘ะปะพะณะธ
    • ะฎะผะพั€
    • ะ ะฐะทะฒะปะตั‡ะตะฝะธั
    • ะะพะฒะพัั‚ะธ ะธ ะŸะพะปะธั‚ะธะบะฐ
    • Howto ะธ ะกั‚ะธะปัŒ
    • Diy ัะฒะพะธะผะธ ั€ัƒะบะฐะผะธ
    • ะžะฑั€ะฐะทะพะฒะฐะฝะธะต
    • ะะฐัƒะบะฐ ะธ ะขะตั…ะฝะพะปะพะณะธะธ
    • ะะตะบะพะผะผะตั€ั‡ะตัะบะธะต ะžั€ะณะฐะฝะธะทะฐั†ะธะธ
  • ะž ัะฐะนั‚ะต

ะกะบะฐั‡ะฐั‚ัŒ ะธะปะธ ัะผะพั‚ั€ะตั‚ัŒ ๐Ÿ‡๐Ÿ”ฌ ๐—ง๐—›๐—˜ ๐—”๐—ก๐—œ๐— ๐—”๐—Ÿ ๐—ง๐—˜๐—ฆ๐—ง๐—œ๐—ก๐—š ๐—˜๐—ก๐——๐—š๐—”๐— ๐—˜: ๐—ช๐—œ๐—ก๐—ก๐—˜๐—ฅ๐—ฆ, ๐——๐—”๐—ง๐—” & ๐——๐—œ๐—ฆ๐—ฅ๐—จ๐—ฃ๐—ง๐—œ๐—ข๐—ก ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—™๐——๐—”'๐—ฆ ๐—ก๐—˜๐—ช ๐—˜๐—ฅ๐—”๐Ÿ”ฌ๐Ÿš€

  • AI Biopharma Playbook
  • 2025-10-25
  • 452
๐Ÿ‡๐Ÿ”ฌ ๐—ง๐—›๐—˜ ๐—”๐—ก๐—œ๐— ๐—”๐—Ÿ ๐—ง๐—˜๐—ฆ๐—ง๐—œ๐—ก๐—š ๐—˜๐—ก๐——๐—š๐—”๐— ๐—˜: ๐—ช๐—œ๐—ก๐—ก๐—˜๐—ฅ๐—ฆ, ๐——๐—”๐—ง๐—” & ๐——๐—œ๐—ฆ๐—ฅ๐—จ๐—ฃ๐—ง๐—œ๐—ข๐—ก ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—™๐——๐—”'๐—ฆ ๐—ก๐—˜๐—ช ๐—˜๐—ฅ๐—”๐Ÿ”ฌ๐Ÿš€
  • ok logo

ะกะบะฐั‡ะฐั‚ัŒ ๐Ÿ‡๐Ÿ”ฌ ๐—ง๐—›๐—˜ ๐—”๐—ก๐—œ๐— ๐—”๐—Ÿ ๐—ง๐—˜๐—ฆ๐—ง๐—œ๐—ก๐—š ๐—˜๐—ก๐——๐—š๐—”๐— ๐—˜: ๐—ช๐—œ๐—ก๐—ก๐—˜๐—ฅ๐—ฆ, ๐——๐—”๐—ง๐—” & ๐——๐—œ๐—ฆ๐—ฅ๐—จ๐—ฃ๐—ง๐—œ๐—ข๐—ก ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—™๐——๐—”'๐—ฆ ๐—ก๐—˜๐—ช ๐—˜๐—ฅ๐—”๐Ÿ”ฌ๐Ÿš€ ะฑะตัะฟะปะฐั‚ะฝะพ ะฒ ะบะฐั‡ะตัั‚ะฒะต 4ะบ (2ะบ / 1080p)

ะฃ ะฝะฐั ะฒั‹ ะผะพะถะตั‚ะต ัะบะฐั‡ะฐั‚ัŒ ะฑะตัะฟะปะฐั‚ะฝะพ ๐Ÿ‡๐Ÿ”ฌ ๐—ง๐—›๐—˜ ๐—”๐—ก๐—œ๐— ๐—”๐—Ÿ ๐—ง๐—˜๐—ฆ๐—ง๐—œ๐—ก๐—š ๐—˜๐—ก๐——๐—š๐—”๐— ๐—˜: ๐—ช๐—œ๐—ก๐—ก๐—˜๐—ฅ๐—ฆ, ๐——๐—”๐—ง๐—” & ๐——๐—œ๐—ฆ๐—ฅ๐—จ๐—ฃ๐—ง๐—œ๐—ข๐—ก ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—™๐——๐—”'๐—ฆ ๐—ก๐—˜๐—ช ๐—˜๐—ฅ๐—”๐Ÿ”ฌ๐Ÿš€ ะธะปะธ ะฟะพัะผะพั‚ั€ะตั‚ัŒ ะฒะธะดะตะพ ั ัŽั‚ัƒะฑะฐ ะฒ ะผะฐะบัะธะผะฐะปัŒะฝะพะผ ะดะพัั‚ัƒะฟะฝะพะผ ะบะฐั‡ะตัั‚ะฒะต.

ะ”ะปั ัะบะฐั‡ะธะฒะฐะฝะธั ะฒั‹ะฑะตั€ะธั‚ะต ะฒะฐั€ะธะฐะฝั‚ ะธะท ั„ะพั€ะผั‹ ะฝะธะถะต:

  • ะ˜ะฝั„ะพั€ะผะฐั†ะธั ะฟะพ ะทะฐะณั€ัƒะทะบะต:

Cะบะฐั‡ะฐั‚ัŒ ะผัƒะทั‹ะบัƒ ๐Ÿ‡๐Ÿ”ฌ ๐—ง๐—›๐—˜ ๐—”๐—ก๐—œ๐— ๐—”๐—Ÿ ๐—ง๐—˜๐—ฆ๐—ง๐—œ๐—ก๐—š ๐—˜๐—ก๐——๐—š๐—”๐— ๐—˜: ๐—ช๐—œ๐—ก๐—ก๐—˜๐—ฅ๐—ฆ, ๐——๐—”๐—ง๐—” & ๐——๐—œ๐—ฆ๐—ฅ๐—จ๐—ฃ๐—ง๐—œ๐—ข๐—ก ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—™๐——๐—”'๐—ฆ ๐—ก๐—˜๐—ช ๐—˜๐—ฅ๐—”๐Ÿ”ฌ๐Ÿš€ ะฑะตัะฟะปะฐั‚ะฝะพ ะฒ ั„ะพั€ะผะฐั‚ะต MP3:

ะ•ัะปะธ ะธะบะพะฝะบะธ ะทะฐะณั€ัƒะทะบะธ ะฝะต ะพั‚ะพะฑั€ะฐะทะธะปะธััŒ, ะŸะžะ–ะะ›ะฃะ™ะกะขะ, ะะะ–ะœะ˜ะขะ• ะ—ะ”ะ•ะกะฌ ะธะปะธ ะพะฑะฝะพะฒะธั‚ะต ัั‚ั€ะฐะฝะธั†ัƒ
ะ•ัะปะธ ัƒ ะฒะฐั ะฒะพะทะฝะธะบะปะธ ั‚ั€ัƒะดะฝะพัั‚ะธ ั ะทะฐะณั€ัƒะทะบะพะน, ะฟะพะถะฐะปัƒะนัั‚ะฐ, ัะฒัะถะธั‚ะตััŒ ั ะฝะฐะผะธ ะฟะพ ะบะพะฝั‚ะฐะบั‚ะฐะผ, ัƒะบะฐะทะฐะฝะฝั‹ะผ ะฒ ะฝะธะถะฝะตะน ั‡ะฐัั‚ะธ ัั‚ั€ะฐะฝะธั†ั‹.
ะกะฟะฐัะธะฑะพ ะทะฐ ะธัะฟะพะปัŒะทะพะฒะฐะฝะธะต ัะตั€ะฒะธัะฐ video2dn.com

ะžะฟะธัะฐะฝะธะต ะบ ะฒะธะดะตะพ ๐Ÿ‡๐Ÿ”ฌ ๐—ง๐—›๐—˜ ๐—”๐—ก๐—œ๐— ๐—”๐—Ÿ ๐—ง๐—˜๐—ฆ๐—ง๐—œ๐—ก๐—š ๐—˜๐—ก๐——๐—š๐—”๐— ๐—˜: ๐—ช๐—œ๐—ก๐—ก๐—˜๐—ฅ๐—ฆ, ๐——๐—”๐—ง๐—” & ๐——๐—œ๐—ฆ๐—ฅ๐—จ๐—ฃ๐—ง๐—œ๐—ข๐—ก ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—™๐——๐—”'๐—ฆ ๐—ก๐—˜๐—ช ๐—˜๐—ฅ๐—”๐Ÿ”ฌ๐Ÿš€

๐Ÿš€ The Animal Testing Endgame: Winners, Data & Disruption in the FDAโ€™s New Era

The FDAโ€™s 2023 phase-out of mandatory animal testing wasnโ€™t just a policy updateโ€”it was the starter pistol for biotechโ€™s most radical transformation since recombinant DNA.

And now? The market is separating winners from laggards fast.

๐Ÿ“Š The New Economics of Non-Animal Models (NAMs)

$2.3B+ invested in AI/NAMs startups since FDA announcement (PitchBook)
72% faster mAb development using AI + organ-chip platforms (Nature Biotech, 2024)

$47M average savings per program by replacing primates with MPS (BIO Industry)

Liver-chips show 83% concordance with clinical data vs. 63% in rodents (FDA pilot)

โš–๏ธ Regulatory Deep Dive: The "Animal Rule Alternative Pathway"
๐Ÿ†• March 2024 FDA guidance allows:

โœ… Full waiver for mAbs with organ-chip PK/PD + AI toxicology (โ‰ฅ80% confidence) โœ… Partial waiver for gene therapies with 3D bioprinted tissue + high-throughput robotics

โš ๏ธ BUT: Must show โ€œtotality of evidenceโ€ across โ‰ฅ3 NAMs (AI + organoid + comp chem)
โš ๏ธ EMA is lagging 12โ€“18 months, opening a transatlantic opportunity gap
๐Ÿ“ˆ Public Companies Riding the $12B

NAMs Wave

1. AI/Computational Drug Discovery
$RXRX (Recursion) โ†’ +142% since FDA news; AI + robotic labs at scale

$EXAI (Exscientia) โ†’ 8/10 Pfizer-backed pipeline programs now animal-free

$SDGR (Schrรถdinger) โ†’ BMS-partnered for in silico toxicity prediction

2. Organ-on-Chip & 3D Bioprinting
$TMO (Thermo Fisher) โ†’ 27% YoY growth in alternative model solutions

$CRL (Charles River Labs) โ†’ NAMs revenue up 39% YoY (Q1 2024)

$LNTH (Lantheus) โ†’ Tumor-on-chip IP surge via microfluidics
3. Lab Automation Enablers

$PACB (PacBio) โ†’ Ex vivo CRISPR QC platforms for AI-enabled screens

$ILMN (Illumina) โ†’ Single-cell seq tech key for organoid validation

๐Ÿค– The Robotic Arms Race

Strateos cloud labs now run 1.2M experiments/year (Moderna/Pfizer)
Opentrons inked $50M automation deal with Charles River
Benchlingโ€™s AI notebooks now auto-flag when animal data can be skipped

๐Ÿ’ฐ Private Disruptors to Watch
Emulate Bio (organ-chip) โ†’ Rumored $2B SPAC in play
Aqemia (AI + quantum physics) โ†’ $167M Series C raised
TissUse (multi-organ chip) โ†’ Strategic bids from PFE, NVS rumored

โš ๏ธ Short Thesis: Whoโ€™s Losing the Future?

$WAT (Waters Corp) โ†’ Traditional animal-focused MS revenue -18%

$BRKR (Bruker) โ†’ Animal MRI division slowing to 2% growth

Legacy primate CROs (private) โ†’ Facing 30% contract cancellations

๐Ÿ”ฎ Investor Playbook: Whatโ€™s Next

July 2024: FDA workshop on โ€œAI-only INDsโ€ (bullish for $EXAI)

Q4 2024: EMA NAMs alignment (tailwind for $CRL, $TMO)

DoD synthetic trial grants pending (watch $RXRX)


#AnimalTestingEndgame
#FDANewEra
#NAMsRevolution
#OrganOnChip
#AIinDrugDiscovery
#BiotechInnovation
#ClinicalTrialsFuture
#NonAnimalTesting
#FDARegulations
#BiotechStocks
#OrganoidTechnology
#3Dbioprinting
#BiomedicalDisruption
#PharmaFuture
#DrugDevelopment

ะšะพะผะผะตะฝั‚ะฐั€ะธะธ

ะ˜ะฝั„ะพั€ะผะฐั†ะธั ะฟะพ ะบะพะผะผะตะฝั‚ะฐั€ะธัะผ ะฒ ั€ะฐะทั€ะฐะฑะพั‚ะบะต

ะŸะพั…ะพะถะธะต ะฒะธะดะตะพ

  • ะž ะฝะฐั
  • ะšะพะฝั‚ะฐะบั‚ั‹
  • ะžั‚ะบะฐะท ะพั‚ ะพั‚ะฒะตั‚ัั‚ะฒะตะฝะฝะพัั‚ะธ - Disclaimer
  • ะฃัะปะพะฒะธั ะธัะฟะพะปัŒะทะพะฒะฐะฝะธั ัะฐะนั‚ะฐ - TOS
  • ะŸะพะปะธั‚ะธะบะฐ ะบะพะฝั„ะธะดะตะฝั†ะธะฐะปัŒะฝะพัั‚ะธ

video2dn Copyright ยฉ 2023 - 2025

ะšะพะฝั‚ะฐะบั‚ั‹ ะดะปั ะฟั€ะฐะฒะพะพะฑะปะฐะดะฐั‚ะตะปะตะน [email protected]